查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423555

到 2030 年流感診斷測試市場預測：按測試類型、最終用戶和地區進行的全球分析

Influenza Diagnostic Tests Market Forecasts to 2030 - Global Analysis By Test Type, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球流感診斷檢測市場規模將達到 11 億美元，預計 2030 年將達到 17 億美元，預測期內複合年成長率為 5.6%。

流感診斷測試是一種醫療程序，旨在識別出現呼吸道症狀的個體是否存在流感病毒。恒溫環型核酸擴增(LAMP) 和基於核酸序列的擴增 (NASBA) 等新技術提供了更快、更方便的替代方案。快速且準確的診斷對於及時治療和有效的公共衛生措施、放大和檢測病毒並提供準確的結果至關重要。

美國疾病管制與預防美國估計，2021-2022年季節，美國將出現900萬例流感病例、400萬例與流感相關的就診、10萬人例與流感相關的住院治療以及5,000例與流感相關的死亡。到 COVID-19 爆發前的最近幾個季度，83% 的死亡病例是老年人。

意識和教育

健康素養計畫教育人們識別流感症狀，了解疾病的潛在嚴重性，並了解診斷測試在有效治療和預防中的作用。公共衛生宣傳活動、教育措施和溝通工作有助於意識提升。此外，醫療保健提供者正在提高識別和應對流感病例的能力，推動了該市場的擴張。

高成本

流感診斷測試的高昂成本可能會阻止醫療保健提供者和患者使用該測試，特別是在資源有限的環境和衛生預算有限的地區。這可能導致診斷不足、治療延遲和疾病管理不善。此外，還可能產生與進行測試相關的額外成本，例如專業費用和檢體採集耗材，從而阻礙市場成長。

診斷技術的進步

分子診斷技術，特別是逆轉錄聚合酶鏈反應（RT-PCR）的顯著進步，提高了流感病毒檢測的敏感度和特異性。這些進步能夠快速且準確地識別病毒株，幫助醫療保健專業人員及時做出決策並管理患者。此外，免疫測量和核酸擴增技術不斷發展，有助於診斷選擇的多樣化。

缺乏意識

醫療保健提供者可能不熟悉每次測試的好處、局限性和結果的適當解釋。這可能導致診斷測試的利用不足或使用不當，從而導致診斷延遲和患者管理不理想。此外，許多人可能沒有意識到它的重要性，這透過減少對檢測服務的需求並導致錯失早期檢測和有效疾病管理的機會來阻礙這個市場。

COVID-19 的影響

COVID-19 大流行從多個方面對流感診斷測試市場產生了負面影響。隨著世界各地的醫療保健系統優先考慮 COVID-19 診斷，對流感診斷測試的整體需求有所下降。 COVID-19 和流感的症狀經常重疊，因此僅根據臨床症狀很難區分兩者。此外，疫情也影響了醫療保健支出的優先順序，這可能會影響流感診斷技術的投資並阻礙市場擴張。

分子診斷分析領域預計將成為預測期內最大的領域

分子診斷檢測領域估計佔據最大佔有率，因為它是利用分子生物學技術檢測和識別流感病毒的檢測類別。這些測試以其高靈敏度、特異性和區分不同流感亞型的能力而聞名。此外，透過逆轉錄聚合酶鍊式反應（RT-PCR）等重要方法，我們正在為更全面地了解流行的流感病毒的遺傳特徵做出貢獻，從而推動這一領域的成長。

研究機構細分市場預計在預測期內複合年成長率最高

研究機構在預測期內將擁有最高的複合年成長率，因為它們透過開展旨在提高現有檢測的敏感性、特異性和效率的研究，在流感診斷領域的發展中發揮關鍵作用，預計這種情況將會發生。研究機構正在努力開發新的診斷檢測方法，包括先進的分子技術、即時檢測設備和血清學檢測方法。此外，研究實驗室在檢驗新診斷技術並提供關鍵資料來指南醫療保健專業人員方面發揮關鍵作用。

比最大的地區

由於擴大採用先進的診斷技術，包括提供更高靈敏度和特異性的 PCR 等分子檢測技術，亞太地區在預測期內佔據了最大的市場佔有率。該地區是 BioConcept、Abbott、Quidel Corporation 和 Thermo Fisher Scientific Inc. 等主要市場的所在地。此外，該地區人口密度高、互聯性強，強調需要採取有效的流感監測和控制措施，從而推動該地區市場的發展。

複合年成長率最高的地區：

由於其發達的醫療基礎設施和對感染疾病的高度認知，預計北美在預測期內將呈現最高的複合年成長率。 RT-PCR 等分子診斷檢測方法的採用越來越多，它們在流感檢測中具有高靈敏度和準確性。此外，診斷技術的持續創新使我們能夠應對新的病毒株和全球健康挑戰，並支持該地區的成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球流感診斷測試市場：按測試類型

  • 分子診斷分析
    • 基於簡單擴增的測定 (SAMBA)
    • RT-PCR
    • 基於核酸序列的擴增檢驗 (NASBAT)
    • 基於恒溫環型核酸擴增的測定（LAMP）
    • 其他分子診斷測定
  • 傳統診斷測試
    • 病毒培養
    • 流感快速診斷檢驗 (RIDT)
    • 血清學檢測
    • 直接螢光抗體測試 (DFAT)
  • 其他測試類型

第6章全球流感診斷測試市場：依最終用戶分類

  • 研究
  • 醫院
  • 診斷中心
  • 其他最終用戶

第7章全球流感診斷測試市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第8章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Becton, Dickinson and Company
  • Coris BioConcept
  • Meridian Bioscience Inc.
  • Abbott
  • Sekisui Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • DiaSorin SpA
  • Quidel Corporation
  • Thermo Fischer Scientific Inc.
Product Code: SMRC24789

According to Stratistics MRC, the Global Influenza Diagnostic Tests Market is accounted for $1.1 billion in 2023 and is expected to reach $1.7 billion by 2030 growing at a CAGR of 5.6% during the forecast period. Influenza diagnostic tests are medical procedures designed to identify the presence of influenza viruses in individuals experiencing respiratory symptoms. Emerging technologies, such as loop-mediated isothermal amplification (LAMP) and nucleic acid sequence-based amplification (NASBA), offer faster and simpler alternatives. Rapid and accurate diagnosis is crucial for prompt treatment and effective public health measures that amplify and detect viruses, providing accurate results.

According to estimates by the Centers for Disease Control and Prevention, there were 9 million flu cases, 4 million influenza-related medical appointments, 100,000 flu-related hospitalizations, and 5,000 flu-related fatalities during the 2021-2022 seasons in the U.S. Similar to recent seasons preceding the COVID-19 outbreak, 83% of fatalities were caused by older people.

Market Dynamics:

Driver:

Increased awareness and education

Health literacy programs educate individuals on recognizing influenza symptoms, understanding the potential severity of the disease, and appreciating the role of diagnostic tests in effective treatment and prevention. Public health campaigns, educational initiatives, and communication efforts contribute to raising awareness among healthcare professionals and the general public. Furthermore, healthcare providers are better equipped to recognize and respond to influenza cases, which are boosting this market expansion.

Restraint:

High cost

The high costs associated with influenza diagnostic tests can deter healthcare providers and patients from utilizing them, particularly in resource-limited settings or regions with constrained healthcare budgets. This can result in underdiagnosis, delayed treatment, and compromised disease management. In addition, there may be additional expenses related to test administration, such as professional fees and specimen collection supplies, hampering market growth.

Opportunity:

Advancements in diagnostic technologies

Molecular diagnostic technologies, notably reverse transcription-polymerase chain reaction (RT-PCR), have seen remarkable progress, offering heightened sensitivity and specificity in detecting influenza viruses. These advancements enable rapid and accurate identification of viral strains, aiding healthcare professionals in timely decision-making and patient management. Moreover, immunoassays and nucleic acid amplification techniques continue to evolve, contributing to a diverse array of diagnostic options, thereby driving this market size.

Threat:

Lack of awareness

Healthcare providers may not be familiar with the advantages, limitations, and proper interpretation of the results associated with each test. This can lead to underutilization or inappropriate utilization of diagnostic tests, potentially resulting in delayed diagnosis and suboptimal patient management. Moreover, many individuals may not be aware of its importance, which contributes to a lower demand for testing services, leading to missed opportunities for early detection and effective disease control and impeding this market.

Covid-19 Impact

The COVID-19 pandemic has had a negative impact on the influenza diagnostic test market in several ways. Healthcare systems worldwide have prioritized COVID-19 diagnostics, leading to a decrease in the overall demand for influenza diagnostic tests. The symptoms of COVID-19 and influenza often overlap, making it challenging to differentiate between the two based solely on clinical presentations. Further, the pandemic has also influenced healthcare spending priorities, potentially affecting investments in diagnostic technologies for influenza and hindering the market's expansion.

The molecular diagnostic assay segment is expected to be the largest during the forecast period

The molecular diagnostic assay segment is estimated to hold the largest share due to a category of tests that utilize molecular biology techniques to detect and identify influenza viruses. These tests are known for their high sensitivity, specificity, and capacity to distinguish between different influenza subtypes. Moreover, they contribute to a more comprehensive understanding of the genetic characteristics of circulating influenza viruses using prominent methods like reverse transcription-polymerase chain reaction (RT-PCR), boosting this segment's growth.

The research laboratories segment is expected to have the highest CAGR during the forecast period

The research laboratories segment is anticipated to have highest CAGR during the forecast period, due to they play a pivotal role in advancing the field of influenza diagnostics by conducting studies that aim to enhance the sensitivity, specificity, and efficiency of existing tests. They engage in the development of novel diagnostic assays, such as advanced molecular techniques, point-of-care testing devices, and serological assays. Furthermore, Research laboratories also play a key role in validating new diagnostic technologies providing essential data to guide healthcare practitioners propelling this segment's expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a growing adoption of advanced diagnostic technologies, including molecular assays like PCR, as they offer higher sensitivity and specificity. This region is home to some of the major key markets, such as BioConcept, Abbott, Quidel Corporation, and Thermo Fisher Scientific Inc. In addition, the region's high population density and interconnectedness emphasize the need for effective influenza surveillance and control measures that drive the market in this region.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to a well-established healthcare infrastructure and a high level of awareness regarding infectious diseases. There is a widespread adoption of molecular diagnostic assays such as RT-PCR, which offer high sensitivity and accuracy in influenza detection. Moreover, continuous innovation in diagnostic technologies, ensuring that they align with emerging viral strains and global health challenges, thereby boosts this region's growth.

Key players in the market

Some of the key players in the Influenza Diagnostic Tests Market include Becton, Dickinson and Company , Coris BioConcept, Meridian Bioscience Inc., Abbott, Sekisui Diagnostics, F. Hoffmann-La Roche Ltd, Hologic Inc., DiaSorin SpA, Quidel Corporation and Thermo Fischer Scientific Inc.

Key Developments:

In September 2023, Navigate BioPharma Services, Inc., announced a strategic collaboration with BD (Becton, Dickinson and Company), to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In July 2023, Thermo Fisher Scientific Inc. announced it has entered into a definitive agreement to acquire CorEvitas, LLC ("CorEvitas"), for approved medical treatments and therapies, from Audax Private Equity ("Audax").

In May 2023, Thermo Fisher, has signed a Memorandum of Understanding ("MOU") with the National Research and Innovation Agency of Indonesia (BRIN, Badan Riset dan Inovasi Nasional) to enable and enhance the country's national research and innovation infrastructure and capability.

Test Types Covered:

  • Molecular Diagnostic Assay
  • Traditional Diagnostic Test
  • Other Test Types

End Users Covered:

  • Research Laboratories
  • Hospitals
  • Diagnostics Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Influenza Diagnostic Tests Market, By Test Type

  • 5.1 Introduction
  • 5.2 Molecular Diagnostic Assay
    • 5.2.1 Simple Amplification-Based Assay (SAMBA)
    • 5.2.2 RT-PCR
    • 5.2.3 Nucleic Acid Sequence-Based Amplification Test (NASBAT)
    • 5.2.4 Loop-Mediated Isothermal Amplification-Based Assay (LAMP)
    • 5.2.5 Other Molecular Diagnostic Assays
  • 5.3 Traditional Diagnostic Test
    • 5.3.1 Viral Culture
    • 5.3.2 Rapid Influenza Diagnostic Test (RIDT)
    • 5.3.3 Serological Assay
    • 5.3.4 Direct Fluorescent Antibody Test (DFAT)
  • 5.4 Other Test Types

6 Global Influenza Diagnostic Tests Market, By End User

  • 6.1 Introduction
  • 6.2 Research Laboratories
  • 6.3 Hospitals
  • 6.4 Diagnostics Centers
  • 6.5 Other End Users

7 Global Influenza Diagnostic Tests Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Becton, Dickinson and Company
  • 9.2 Coris BioConcept
  • 9.3 Meridian Bioscience Inc.
  • 9.4 Abbott
  • 9.5 Sekisui Diagnostics
  • 9.6 F. Hoffmann-La Roche Ltd
  • 9.7 Hologic Inc.
  • 9.8 DiaSorin SpA
  • 9.9 Quidel Corporation
  • 9.10 Thermo Fischer Scientific Inc.

List of Tables

  • Table 1 Global Influenza Diagnostic Tests Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 3 Global Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 4 Global Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 5 Global Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 6 Global Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 7 Global Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 8 Global Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 9 Global Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 10 Global Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 7 Global Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 8 Global Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 9 Global Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 14 Global Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 15 Global Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 16 Global Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 17 Global Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 18 Global Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 19 Global Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 20 North America Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 22 North America Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 23 North America Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 24 North America Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 25 North America Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 26 North America Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 27 North America Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 28 North America Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 29 North America Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 30 North America Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 31 North America Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 32 North America Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 33 North America Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 34 North America Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 North America Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 36 North America Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 37 North America Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 38 North America Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 39 Europe Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 41 Europe Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 42 Europe Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 43 Europe Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 44 Europe Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 45 Europe Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 46 Europe Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 47 Europe Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 48 Europe Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 49 Europe Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 50 Europe Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 51 Europe Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 52 Europe Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 53 Europe Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 54 Europe Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 55 Europe Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 56 Europe Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 57 Europe Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 58 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 61 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 62 Asia Pacific Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 63 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 64 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 65 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 66 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 67 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 68 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 69 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 70 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 71 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 72 Asia Pacific Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 74 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 75 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 76 Asia Pacific Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 77 South America Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 79 South America Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 80 South America Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 81 South America Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 82 South America Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 83 South America Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 84 South America Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 85 South America Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 86 South America Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 87 South America Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 88 South America Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 89 South America Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 90 South America Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 91 South America Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 92 South America Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 93 South America Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 94 South America Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 95 South America Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 96 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 99 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Simple Amplification-Based Assay (SAMBA) (2021-2030) ($MN)
  • Table 100 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By RT-PCR (2021-2030) ($MN)
  • Table 101 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Nucleic Acid Sequence-Based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 102 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Loop-Mediated Isothermal Amplification-Based Assay (LAMP) (2021-2030) ($MN)
  • Table 103 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other Molecular Diagnostic Assays (2021-2030) ($MN)
  • Table 104 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 105 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 106 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 107 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Serological Assay (2021-2030) ($MN)
  • Table 108 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 109 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 110 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By End User (2021-2030) ($MN)
  • Table 111 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Research Laboratories (2021-2030) ($MN)
  • Table 112 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 113 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Diagnostics Centers (2021-2030) ($MN)
  • Table 114 Middle East & Africa Influenza Diagnostic Tests Market Outlook, By Other End Users (2021-2030) ($MN)